SEARCH WITHIN CONTENT
Citation Information : Immunohematology. Volume 18, Issue 3, Pages 71-77, DOI: https://doi.org/10.21307/immunohematology-2019-513
License : (Transfer of Copyright)
Published Online: 14-October-2020
In the United States, the Food and Drug Administration mandates that red blood cells (RBCs) for antibody detection possess the following antigens: C, D, E, c, e, M, N, S, s, P1, Lea , Leb , K, k, Fya, Fyb, Jka, and Jkb. Although not required, it is generally agreed that homozygosity for C, D, E, c, e, Fya, and Jka is also preferable.There is no requirement for low-frequency antigens to be present.However, manufacturers of antibody detection RBCs receive requests for these RBCs to possess Cw, Kpa, and Wra.There are no data to support the considerable expense and effort involved in providing RBCs that possess low-frequency antigens such as Cw, Kpa, and Wra. The risk of clinically-significant hemolytic transfusion reactions occurring when such antibodies are not detected because antibody detection RBCs lack such antigens is about 1 in 500,000 to 1 in 1 million transfusions.